Drug intelligence / Profile preview

ibuprofen + methocarbamol (Sanfer)

Development stage
Unknown
Lead developer
Sanfer
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

Algitrin is a combination analgesic and muscle relaxant medication developed and marketed by Sanfer (Invekra). It typically contains ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), and methocarbamol, a central nervous system (CNS) depressant. Ibuprofen exerts its effects by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, thereby reducing the synthesis of prostaglandins that mediate pain and inflammation. Methocarbamol acts as a muscle relaxant through general CNS depression, specifically by inhibiting polysynaptic reflexes, although its exact molecular target remains uncharacterized. The product is available in various forms, including tablets, gels, and syrups, and is primarily indicated for the relief of musculoskeletal pain, muscle spasms, and associated inflammatory conditions.

Brand names
Algitrin
Other names
Algitrin
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on ibuprofen + methocarbamol (Sanfer).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibuprofen + methocarbamol (Sanfer).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call